Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer.
Jun ZhangBei SunXianhui RuanXiukun HouJingtai ZhiXiangrui MengXiangqian ZhengMing GaoPublished in: Cancer biology & medicine (2021)
Taken together, our results showed that the HBXIP-MEK interaction promoted oncogenesis via the MAPK/ERK pathway, which may serve as a novel therapeutic target for cancers in which MAPK/ERK signaling is a dominant feature.